中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
20期
48-49,50
,共3页
非小细胞肺癌%红景天注射液%奥沙利铂%吉西他滨
非小細胞肺癌%紅景天註射液%奧沙利鉑%吉西他濱
비소세포폐암%홍경천주사액%오사리박%길서타빈
non small cell lung cancer ( NSCLC )%Rhodiola Injection%oxaliplatin%gemcitabine
目的：观察红景天注射液联合奥沙利铂( L-OHP )+吉西他滨（GEM）化学治疗(简称化疗)治疗进展期非小细胞肺癌（NSCLC）的临床疗效。方法按入院日期单双号将收治的98例进展期NSCLC患者分为试验组（50例）和对照组（48例），两组均采用L-OHP+GEM 4个周期化疗方案，试验组每个化疗周期加用红景天注射液10 d，记录化疗期间药物毒性反应，化疗1个周期后对比两组细胞免疫水平变化，化疗结束后比较两组临床疗效。结果化疗1个周期后，试验组和对照组CD4+分别为（41.0±5.9）%和(37.5±6.3)%，试验组CD4+/CD8+明显高于对照组水平（ P<0.05）。试验组与对照组化疗总有效率分别为66.00%和47.92%，差异无统计学意义（χ2=3.270， P=0.071）；化疗后试验组Karnofsky ( KPS )评分为（80.1±5.8）分，明显高于对照组的（77.5±6.1）分（ t=2.163，P=0.033）。化疗期间试验组胃肠道反应、血小板减少、粒细胞减少、末梢神经毒性、肝功损害、肾功损害发生率均低于对照组水平，但差异无统计学意义。结论红景天注射液联合L-OPH+GEM化疗方案治疗进展期NSCLC患者，能明显改善细胞免疫功能，辅助提高抗肿瘤近期疗效与抗瘤治疗的耐受性。
目的：觀察紅景天註射液聯閤奧沙利鉑( L-OHP )+吉西他濱（GEM）化學治療(簡稱化療)治療進展期非小細胞肺癌（NSCLC）的臨床療效。方法按入院日期單雙號將收治的98例進展期NSCLC患者分為試驗組（50例）和對照組（48例），兩組均採用L-OHP+GEM 4箇週期化療方案，試驗組每箇化療週期加用紅景天註射液10 d，記錄化療期間藥物毒性反應，化療1箇週期後對比兩組細胞免疫水平變化，化療結束後比較兩組臨床療效。結果化療1箇週期後，試驗組和對照組CD4+分彆為（41.0±5.9）%和(37.5±6.3)%，試驗組CD4+/CD8+明顯高于對照組水平（ P<0.05）。試驗組與對照組化療總有效率分彆為66.00%和47.92%，差異無統計學意義（χ2=3.270， P=0.071）；化療後試驗組Karnofsky ( KPS )評分為（80.1±5.8）分，明顯高于對照組的（77.5±6.1）分（ t=2.163，P=0.033）。化療期間試驗組胃腸道反應、血小闆減少、粒細胞減少、末梢神經毒性、肝功損害、腎功損害髮生率均低于對照組水平，但差異無統計學意義。結論紅景天註射液聯閤L-OPH+GEM化療方案治療進展期NSCLC患者，能明顯改善細胞免疫功能，輔助提高抗腫瘤近期療效與抗瘤治療的耐受性。
목적：관찰홍경천주사액연합오사리박( L-OHP )+길서타빈（GEM）화학치료(간칭화료)치료진전기비소세포폐암（NSCLC）적림상료효。방법안입원일기단쌍호장수치적98례진전기NSCLC환자분위시험조（50례）화대조조（48례），량조균채용L-OHP+GEM 4개주기화료방안，시험조매개화료주기가용홍경천주사액10 d，기록화료기간약물독성반응，화료1개주기후대비량조세포면역수평변화，화료결속후비교량조림상료효。결과화료1개주기후，시험조화대조조CD4+분별위（41.0±5.9）%화(37.5±6.3)%，시험조CD4+/CD8+명현고우대조조수평（ P<0.05）。시험조여대조조화료총유효솔분별위66.00%화47.92%，차이무통계학의의（χ2=3.270， P=0.071）；화료후시험조Karnofsky ( KPS )평분위（80.1±5.8）분，명현고우대조조적（77.5±6.1）분（ t=2.163，P=0.033）。화료기간시험조위장도반응、혈소판감소、립세포감소、말소신경독성、간공손해、신공손해발생솔균저우대조조수평，단차이무통계학의의。결론홍경천주사액연합L-OPH+GEM화료방안치료진전기NSCLC환자，능명현개선세포면역공능，보조제고항종류근기료효여항류치료적내수성。
Objective To observe the clinical efficacy of Rhodiola Injection combined with oxaliplatin ( L-OHP ) and gemcitabine ( GEM ) in treating advanced non small cell lung cancer ( NSCLC ) . Methods 98 patients with advanced NSCLS were selected and randomly di-vided into the experimental group ( n=50 ) and the control group ( n=48 ) according to odd or even number of admission day. The two groups adopted the 4-cycle chemotherapy with L-OHP and GEM. The experimental group was added with Rhodiola Injection for 10 d in each cycle. The drug toxicity reactions during treatment were recorded. The changes of cellular immune level were compared between 2 groups after 1-cycle chemotherapy and the clinical curative effects after the end of chemotherapy were compared between 2 groups. Results After 1-cycle chemotherapy, CD4 +, CD4 + /CD8 + in the experimental group were significantly higher than those in the control group [ ( 41 ± 5. 9 )% vs. ( 37. 5 ± 6. 3 )%, P<0. 05 ] . The total effective rates in the experimental group and the control group were 66. 00% and 47. 92% respectively, the differences had no statistical significance (χ2=3. 270, P=0. 071 ); the KPS score after chemotherapy in the experimental group was ( 80. 1 ± 5. 8 ) points, which was significantly higher than ( 77. 5 ± 6. 1 ) points in the control group ( t=2. 163, P=0. 033 ) . The occurrence rates of drug toxicities such as gastrointestinal reaction, thrombocytopenia, neutropenia, pe-ripheral neurotoxicity, liver and renal function damage in the experimental group were all lower than those in the control group, but the difference had no statistical significance. Conclusion The chemotherapy scheme of Rhodiola Injection combined with L-OPH and GEM in treating advanced NSCLC can significantly improve the cellular immune function and auxiliarily increase the short term clinical effi-cacy and tolerance to chemotherapy.
